Physician profile
Patrick James Henderson
NPI 1902150527
$3,533.41
in general payments reported to CMS, 2019-2025
22 companies · $1,226 in 2025
The $1,226 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $168 · 2021: $606 · 2022: $450 · 2023: $130 · 2024: $830 · 2025: $1,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,501 · Travel and Lodging: $685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,501.08 |
| Travel and Lodging | $684.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,532.54 | 2020-2025 | Triclip, Thoratec Heartmate 3 Lvas Implant Kit, Assurity |
| Heartflow, INC. | $557.30 | 2024 | |
| Novartis Pharmaceuticals Corporation | $249.70 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $209.51 | 2021-2022 | |
| Boston Scientific Corporation | $190.17 | 2022-2024 | |
| Penumbra, INC. | $164.91 | 2025 | Indigo System |
| Edwards Lifesciences Corporation | $123.33 | 2019 | |
| Amgen INC. | $103.18 | 2021-2025 | Repatha, Repatha |
| Alnylam Pharmaceuticals INC. | $59.00 | 2023-2024 | Onpattro |
| Medtronic, INC. | $50.86 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $45.75 | 2022-2023 | Farxiga |
| Angiodynamics, INC. | $38.88 | 2025 | Alphavac |
| Atricure, INC. | $38.09 | 2021 | |
| Abiomed | $35.55 | 2024 | Impella |
| Bracco Diagnostics INC. | $23.50 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $20.06 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Esperion Therapeutics, INC. | $18.50 | 2022 | |
| Pfizer INC. | $17.79 | 2022 | |
| Avanir Pharmaceuticals, INC. | $16.53 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.43 | 2022 | |
| Merck Sharp & Dohme LLC | $14.02 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $8.81 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.